vs
Side-by-side financial comparison of AST SpaceMobile, Inc. (ASTS) and Xeris Biopharma Holdings, Inc. (XERS). Click either name above to swap in a different company.
Xeris Biopharma Holdings, Inc. is the larger business by last-quarter revenue ($85.8M vs $54.3M, roughly 1.6× AST SpaceMobile, Inc.). Over the past eight quarters, AST SpaceMobile, Inc.'s revenue compounded faster (173.4% CAGR vs 45.3%).
AST SpaceMobile, Inc. is a publicly traded satellite designer and manufacturer based in Midland, Texas, United States. The company is building the SpaceMobile satellite constellation, a space-based cellular broadband network designed to connect directly to standard, unmodified smartphones. The network is intended to deliver 4G and 5G broadband coverage globally, particularly in remote and underserved regions.
Xeris Biopharma Holdings, Inc. is a specialty biopharmaceutical company that develops and commercializes targeted therapies for rare endocrine, metabolic, and dermatological conditions. It operates across global markets, focusing on delivering accessible, easy-to-administer treatment options for underserved patient segments.
ASTS vs XERS — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $54.3M | $85.8M |
| Net Profit | — | $11.1M |
| Gross Margin | — | — |
| Operating Margin | -560.4% | 19.5% |
| Net Margin | — | 12.9% |
| Revenue YoY | — | 42.8% |
| Net Profit YoY | — | 316.7% |
| EPS (diluted) | — | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $54.3M | — | ||
| Q4 25 | $54.3M | $85.8M | ||
| Q3 25 | $14.7M | $74.4M | ||
| Q2 25 | — | $71.5M | ||
| Q1 25 | — | $60.1M | ||
| Q4 24 | — | $60.1M | ||
| Q3 24 | — | $54.3M | ||
| Q2 24 | — | $48.1M |
| Q1 26 | — | — | ||
| Q4 25 | $-74.0M | $11.1M | ||
| Q3 25 | $-122.9M | $621.0K | ||
| Q2 25 | — | $-1.9M | ||
| Q1 25 | — | $-9.2M | ||
| Q4 24 | — | $-5.1M | ||
| Q3 24 | — | $-15.7M | ||
| Q2 24 | — | $-15.0M |
| Q1 26 | -560.4% | — | ||
| Q4 25 | -175.0% | 19.5% | ||
| Q3 25 | -1109.0% | 9.0% | ||
| Q2 25 | — | 6.3% | ||
| Q1 25 | — | -5.1% | ||
| Q4 24 | — | 2.8% | ||
| Q3 24 | — | -23.8% | ||
| Q2 24 | — | -17.0% |
| Q1 26 | — | — | ||
| Q4 25 | -136.2% | 12.9% | ||
| Q3 25 | -833.7% | 0.8% | ||
| Q2 25 | — | -2.7% | ||
| Q1 25 | — | -15.3% | ||
| Q4 24 | — | -8.5% | ||
| Q3 24 | — | -29.0% | ||
| Q2 24 | — | -31.2% |
| Q1 26 | — | — | ||
| Q4 25 | — | $0.07 | ||
| Q3 25 | — | $0.00 | ||
| Q2 25 | — | $-0.01 | ||
| Q1 25 | — | $-0.06 | ||
| Q4 24 | — | $-0.02 | ||
| Q3 24 | — | $-0.11 | ||
| Q2 24 | — | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.3B | $111.0M |
| Total DebtLower is stronger | $12.0M | $220.3M |
| Stockholders' EquityBook value | $2.4B | $13.7M |
| Total Assets | $5.0B | $383.5M |
| Debt / EquityLower = less leverage | 0.01× | 16.10× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $2.3B | — | ||
| Q4 25 | $4.3B | $111.0M | ||
| Q3 25 | $2.4B | $91.6M | ||
| Q2 25 | — | $59.3M | ||
| Q1 25 | — | $58.4M | ||
| Q4 24 | — | $71.6M | ||
| Q3 24 | — | $69.4M | ||
| Q2 24 | — | $77.6M |
| Q1 26 | $12.0M | — | ||
| Q4 25 | — | $220.3M | ||
| Q3 25 | — | $219.5M | ||
| Q2 25 | — | $218.6M | ||
| Q1 25 | — | $229.8M | ||
| Q4 24 | — | $232.1M | ||
| Q3 24 | — | $216.2M | ||
| Q2 24 | — | $230.5M |
| Q1 26 | $2.4B | — | ||
| Q4 25 | $2.4B | $13.7M | ||
| Q3 25 | $1.6B | $-861.0K | ||
| Q2 25 | — | $-19.3M | ||
| Q1 25 | — | $-35.1M | ||
| Q4 24 | — | $-29.6M | ||
| Q3 24 | — | $-28.3M | ||
| Q2 24 | — | $-19.3M |
| Q1 26 | $5.0B | — | ||
| Q4 25 | $5.0B | $383.5M | ||
| Q3 25 | $2.6B | $370.2M | ||
| Q2 25 | — | $334.7M | ||
| Q1 25 | — | $315.5M | ||
| Q4 24 | — | $323.1M | ||
| Q3 24 | — | $321.1M | ||
| Q2 24 | — | $331.7M |
| Q1 26 | 0.01× | — | ||
| Q4 25 | — | 16.10× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $20.0M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | 1.81× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $65.0M | $20.0M | ||
| Q3 25 | $-64.5M | $18.4M | ||
| Q2 25 | — | $182.0K | ||
| Q1 25 | — | $-10.0M | ||
| Q4 24 | — | $2.0M | ||
| Q3 24 | — | $-8.3M | ||
| Q2 24 | — | $-10.3M |
| Q1 26 | — | — | ||
| Q4 25 | $-330.7M | — | ||
| Q3 25 | $-302.9M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | -609.0% | — | ||
| Q3 25 | -2055.0% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | 728.7% | — | ||
| Q3 25 | 1617.6% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | 1.81× | ||
| Q3 25 | — | 29.68× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ASTS
Segment breakdown not available.
XERS
| Products | $83.4M | 97% |
| Other | $2.4M | 3% |
